The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Shematic representation for the mechanism of the swelling pressure: (a)soil without added fiber; (b)soil with added fiber. by Yonggang Huang (223155)

Mean AIV-H9N2 shedding titer (Log₁₀) in oropharyngeal swabs. by Oumayma Arbani (21001472)

Cardiac performance and hemolymph distribution are significantly reduced upon valve malformation. by Christian Meyer (6035)

Autophagy significantly influences the apoptotic levels of RGCs in glaucomatous mouse eyes. by Hongmei Qian (538647)

Densities of pAkt/tAkt bands from Western blots were quantified. by Tucker Hopkins (20790529)

Area under the curve responses to breakfast, lunch and dinner during the baseline week and follow-up week. by Jennifer S. Barrett (20308363)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

LDL-C meta-analysis showing in (A) the overall effects of different statin types versus placebo and (B) stratified by statin treatment duration for 3-4 months and longer than 4 mon... by Solima Sabeel (9545738)

Subjects:

Characteristics of HACE respondents by year. by David Henderson (4612354)

“…</p><p>Results</p><p>Overall patient satisfaction with general practice declined significantly over the 10 years, with mean positive scores dropping from 90.1% in 2011/12 to 70.5% in 2021/22. …”

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects: